• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Heartbeam Inc. (Amendment)

    1/10/23 2:21:43 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    SC 13G/A 1 beat0123.txt SABBY 13GA BEAT 1.10.23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* Heartbeam, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 42238H 108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ? CUSIP No. 42238H 108 1. NAME OF REPORTING PERSONS Sabby Volatility Warrant Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 271,788 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 271,788 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 271,788 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.40 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO? CUSIP No. 42238H 108 1. NAME OF REPORTING PERSONS Sabby Management, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 271,788 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 271,788 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 271,788 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.40 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO CUSIP No. 42238H 108 1. NAME OF REPORTING PERSONS Hal Mintz 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 271,788 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 271,788 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 271,788 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.40 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN? CUSIP No. 42238H 108 Item 1. (a). Name of Issuer: Heartbeam, Inc. (b). Address of issuer's principal executive offices: 2118 WALSH AVE., SUITE 210 SANTA CLARA, CA 95050 Item 2. (a). Name of person filing: Sabby Volatility Warrant Master Fund, Ltd. Sabby Management, LLC Hal Mintz (b). Address or principal business office or, if none, residence: Sabby Volatility Warrant Master Fund, Ltd. c/o Ogier Fiduciary Services (Cayman) Limited 89 Nexus Way, Camana Bay Grand Cayman KY1-9007 Cayman Islands Sabby Management, LLC 115 Hidden Hills Dr Spicewood TX 78669 Hal Mintz c/o Sabby Management, LLC 115 Hidden Hills Dr Spicewood TX 78669 (c). Citizenship: Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands Sabby Management, LLC - Delaware, USA Hal Mintz - USA (d). Title of class of securities: Common stock (the Common Stock) (e). CUSIP No.: 42238H 108 Item 3. If This Statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [_] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [_] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: Sabby Volatility Warrant Master Fund, Ltd. - 271,788 Sabby Management, LLC - 271,788 Hal Mintz - 271,788 (b) Percent of class: Sabby Volatility Warrant Master Fund, Ltd. - 3.40% Sabby Management, LLC - 3.40% Hal Mintz - 3.40% (c) Number of shares as to which the person has: Sabby Volatility Warrant Master Fund, Ltd. (i) Sole power to vote or to direct the vote 0 , (ii) Shared power to vote or to direct the vote 271,788 , (iii) Sole power to dispose or to direct the disposition of 0 , (iv) Shared power to dispose or to direct the disposition of 271,788 . Sabby Management, LLC (i) Sole power to vote or to direct the vote 0 , (ii) Shared power to vote or to direct the vote 271,788 , (iii) Sole power to dispose or to direct the disposition of 0 , (iv) Shared power to dispose or to direct the disposition of 271,788 . Hal Mintz (i) Sole power to vote or to direct the vote 0 , (ii) Shared power to vote or to direct the vote 271,788 , (iii) Sole power to dispose or to direct the disposition of 0 , (iv) Shared power to dispose or to direct the disposition of 271,788 . As calculated in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended, (i) Sabby Volatility Master Fund, Ltd. beneficially owns 271,788 shares of the Issuer's common stock (Common Stock), representing approximately 3.40% of the Common Stock,and (ii) Sabby Management, LLC and Hal Mintz each beneficially own 271,788 shares of the Common Stock, representing approximately 3.40% of the Common Stock. Sabby Management, LLC and Hal Mintz do not directly own any shares of Common Stock, but each indirectly owns 271,788 shares of Common Stock. Sabby Management, LLC, a Delaware limited liability company,indirectly owns 271,788 shares of Common Stock because it serves as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands company. Mr. Mintz indirectly owns 271,788 shares of Common Stock in his capacity as manager of Sabby Management, LLC. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. ? Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable ? Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. ? SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 10, 2023 (Date) Sabby Volatility Warrant Master Fund, Ltd. By: /s/ Harry Thompson Name: Harry Thompson Title: Authorized Person of TDF Management Ltd., a Director Sabby Management, LLC* By: /s/ Robert Grundstein Name: Robert Grundstein Title: Chief Operating Officer /s/ Hal Mintz* Hal Mintz *This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein. The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). EXHIBIT 1 ---------- JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Heartbeam, Inc. is filed jointly, on behalf of each of them. Dated: January 10, 2023 Sabby Volatility Warrant Master Fund, Ltd. By: /s/ Harry Thompson Name: Harry Thompson Title: Authorized Person of TDF Management Ltd., a Director Sabby Management, LLC By: /s/ Robert Grundstein Name: Robert Grundstein Title: Chief Operating Officer /s/ Hal Mintz Hal Mintz
    Get the next $BEAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Cruickshank Tim

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:06:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Eno Robert Paul

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:05:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Technology Officer Persen Kenneth Harry

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      5/1/25 11:03:46 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on BioTelemetry with a new price target

      Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00

      12/20/21 7:19:06 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Heartbeam Inc.

      DEF 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/28/25 9:12:56 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Heartbeam Inc.

      PRE 14A - HeartBeam, Inc. (0001779372) (Filer)

      5/16/25 9:10:31 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Heartbeam Inc.

      10-Q - HeartBeam, Inc. (0001779372) (Filer)

      5/13/25 4:04:02 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Financials

    Live finance-specific insights

    See more
    • HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2025, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the web

      5/1/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

      HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

      2/27/25 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Reports Third Quarter 2024 Results

      Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

      11/7/24 4:05:00 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • MDB Capital Holdings Provides First Quarter 2025 Update

      Addison, TX, May 21, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, today provides an update on operations through and subsequent to the quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights Closed a public offering of common stock for HeartBeam, Inc (NASDAQ:BEAT) with gross proceeds of approximately $11.5 million. Completed LOIs for 3 new "Big Idea" companies to launch in 2025.Increased our MDBH shareholder base by 4.5% during Q1 2025.Onboarded 111 new MDB Direct accounts during the first quarter, a 26% i

      5/21/25 9:00:00 AM ET
      $BEAT
      $MDBH
      Medical/Dental Instruments
      Health Care
      Finance: Consumer Services
      Finance
    • HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio

      First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology Second patent expands the use of risk-based diagnostic algorithms into HeartBeam's product portfolio around wearable devices HeartBeam now has 20 issued patents worldwide, cementing Company's leadership in cardiac monitoring innovation HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling futur

      5/6/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      10/25/23 4:01:55 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      8/28/23 4:26:34 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Heartbeam Inc.

      SC 13D - HeartBeam, Inc. (0001779372) (Subject)

      6/2/23 2:36:13 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    See more
    • HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

      Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

      5/5/25 7:00:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

      First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

      12/16/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

      Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

      10/17/24 8:31:00 AM ET
      $BEAT
      Medical/Dental Instruments
      Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 8:00:22 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care
    • CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

      4 - HeartBeam, Inc. (0001779372) (Issuer)

      2/21/25 7:55:14 PM ET
      $BEAT
      Medical/Dental Instruments
      Health Care